Q3 revenues declined 16% YoY to | 3769.3 crore due to divestment of Japanese business. Excluding Japan, YoY growth was mere 2.7%. Strong growth in domestic braded formulations was largely offset by decline in US generic business. Domestic formulations grew 9% YoY to | 1296.9 crore (Idirect estimate: | 1344.9 crore). US revenues grew 3.9% YoY to | 1376.6 crore (I-direct estimate: | 1412.8 crore). EBITDA margins contracted 532 bps YoY to 11.4% mainly due to higher sales promotional expenses, remedial cost and R&D; spend. EBITDA de-grew 37% YoY to | 430 crore. Exceptional items include impairment of | 1579.8 crore related to certain acquired IPs...